Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study
French drug major Sanofi (Euronext: SAN) and US biotech company Regeneron's (Nasdaq: REGN) dupilumab has met all primary and secondary endpoints in their Phase IIa proof-of-concept study of the drug.
Dupilumab is an investigational therapy that blocks interleukin (IL)-4 and IL-13 signaling in patients with moderate-to-severe chronic sinusitis with nasal polyps who did not respond to intranasal corticosteroids.
The study showed dupilumab gave a statistically-significant improvement in the size of nasal polyps as measured by endoscopic nasal polyp score, which was the primary endpoint. Secondary endpoints which were objective measures of sinusitis by CT scan, nasal air flow and patient-reported symptoms all sustained statistically significant improvements.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze